CN101043822A - 含有可发酵多糖的组合物 - Google Patents
含有可发酵多糖的组合物 Download PDFInfo
- Publication number
- CN101043822A CN101043822A CNA2005800355224A CN200580035522A CN101043822A CN 101043822 A CN101043822 A CN 101043822A CN A2005800355224 A CNA2005800355224 A CN A2005800355224A CN 200580035522 A CN200580035522 A CN 200580035522A CN 101043822 A CN101043822 A CN 101043822A
- Authority
- CN
- China
- Prior art keywords
- composition
- indigestible
- gram
- partial hydrolysis
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 116
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 52
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 52
- 150000004676 glycans Chemical class 0.000 title claims abstract description 51
- 235000016709 nutrition Nutrition 0.000 claims abstract description 7
- 230000007062 hydrolysis Effects 0.000 claims description 46
- 238000006460 hydrolysis reaction Methods 0.000 claims description 46
- 229920001206 natural gum Polymers 0.000 claims description 25
- 229920001353 Dextrin Polymers 0.000 claims description 19
- 239000004375 Dextrin Substances 0.000 claims description 19
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 17
- 150000001720 carbohydrates Chemical class 0.000 claims description 17
- 229920002907 Guar gum Polymers 0.000 claims description 16
- 235000010417 guar gum Nutrition 0.000 claims description 16
- 239000000665 guar gum Substances 0.000 claims description 16
- 229960002154 guar gum Drugs 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 238000006116 polymerization reaction Methods 0.000 claims description 13
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 claims description 12
- 235000019197 fats Nutrition 0.000 claims description 12
- 210000000936 intestine Anatomy 0.000 claims description 12
- 229940118199 levulan Drugs 0.000 claims description 12
- 235000020778 linoleic acid Nutrition 0.000 claims description 12
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 12
- 229960004232 linoleic acid Drugs 0.000 claims description 10
- 208000004998 Abdominal Pain Diseases 0.000 claims description 8
- 229920000926 Galactomannan Polymers 0.000 claims description 8
- 208000002881 Colic Diseases 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 206010012735 Diarrhoea Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 230000035764 nutrition Effects 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 230000003203 everyday effect Effects 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 208000012657 Atopic disease Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 235000021281 monounsaturated fatty acids Nutrition 0.000 claims description 2
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 46
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 30
- 238000000855 fermentation Methods 0.000 description 25
- 230000004151 fermentation Effects 0.000 description 25
- 229920001202 Inulin Polymers 0.000 description 23
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 23
- 229940029339 inulin Drugs 0.000 description 23
- 239000004310 lactic acid Substances 0.000 description 23
- 235000014655 lactic acid Nutrition 0.000 description 23
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 18
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 16
- 241000186000 Bifidobacterium Species 0.000 description 14
- 235000014633 carbohydrates Nutrition 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 10
- 210000003608 fece Anatomy 0.000 description 10
- 235000013406 prebiotics Nutrition 0.000 description 10
- 229940005605 valeric acid Drugs 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 8
- 210000001072 colon Anatomy 0.000 description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000009467 reduction Effects 0.000 description 7
- 235000013350 formula milk Nutrition 0.000 description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 5
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 5
- 244000046052 Phaseolus vulgaris Species 0.000 description 5
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 5
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 229920001542 oligosaccharide Polymers 0.000 description 5
- 150000002482 oligosaccharides Chemical class 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 230000002079 cooperative effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 235000019260 propionic acid Nutrition 0.000 description 4
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical class CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 3
- 108010076119 Caseins Proteins 0.000 description 3
- 102000011632 Caseins Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 241000736262 Microbiota Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 235000020256 human milk Nutrition 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 235000021125 infant nutrition Nutrition 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- -1 polysaccharide carbohydrate Chemical class 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229960003080 taurine Drugs 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- 244000303965 Cyamopsis psoralioides Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940029830 benefiber Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 2
- 230000003446 memory effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 235000017399 Caesalpinia tinctoria Nutrition 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 235000008222 Cyamopsis psoralioides Nutrition 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 101710094902 Legumin Proteins 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 241000388430 Tara Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241001541238 Vachellia tortilis subsp. raddiana Species 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- LKDRXBCSQODPBY-ZXXMMSQZSA-N alpha-D-fructopyranose Chemical group OC[C@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-ZXXMMSQZSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- GZCGUPFRVQAUEE-UHFFFAOYSA-N alpha-D-galactose Natural products OCC(O)C(O)C(O)C(O)C=O GZCGUPFRVQAUEE-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-UHFFFAOYSA-N alpha-D-glucopyranose Natural products OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037358 bacterial metabolism Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WQZGKKKJIJFFOK-RWOPYEJCSA-N beta-D-mannose Chemical compound OC[C@H]1O[C@@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-RWOPYEJCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000001847 bifidogenic effect Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000009133 cooperative interaction Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- NEKNNCABDXGBEN-UHFFFAOYSA-L disodium;4-(4-chloro-2-methylphenoxy)butanoate;4-(2,4-dichlorophenoxy)butanoate Chemical compound [Na+].[Na+].CC1=CC(Cl)=CC=C1OCCCC([O-])=O.[O-]C(=O)CCCOC1=CC=C(Cl)C=C1Cl NEKNNCABDXGBEN-UHFFFAOYSA-L 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000020218 follow-on milk formula Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960003082 galactose Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 230000003050 macronutrient Effects 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 239000010499 rapseed oil Substances 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
- 229940046307 sodium thioglycolate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/238—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seeds, e.g. locust bean gum or guar gum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/244—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/35—Degradation products of starch, e.g. hydrolysates, dextrins; Enzymatically modified starches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Mycology (AREA)
- Pediatric Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及一种营养组合物,每100g组合物干重包含0.1至15克聚合度在10和300之间的可发酵的部分水解树胶,并且每100克组合物干重包含0.1至15克不同于水解树胶的DP在10和300之间的可发酵、不可消化的多糖。
Description
技术领域
本发明涉及包含益生元多糖的协同混合物的婴儿用营养配方食品(nutritional formula)和包含多糖混合物的营养组合物。
背景技术
人类大肠的微生物区系在人类健康中起着关键性的作用。微生物区系可通过饮食摄入调节。未消化的碳水化合物和未消化的蛋白质由细菌代谢,生成了短链脂肪酸(SCFA)——如乙酸、丙酸、丁酸和戊酸——作为代谢的主要终产物,这些SCFA可随后由寄主利用。细菌发酵的终产物的其它实例为乳酸和气体。
乳酸杆菌(Lactobacilli)生成乳酸或乳酸和乙酸。双歧杆菌(Bifidobacteria)生成乳酸和乙酸。双歧杆菌、乳酸杆菌和其它乳酸细菌对碳水化合物的发酵通常不会导致生成丙酸、丁酸、异丁酸、戊酸和异戊酸。上述SCFA表明其它种类细菌——如梭菌(Clostridia)类杆菌(Bacteroide)或者肠杆菌(Enterobacteriaca)——对碳水化合物的发酵,或者表明对蛋白质的发酵。因此,肠内乳酸和乙酸的(相对)增加以及与此同时的其它SCFA的(相对)减少表明乳酸细菌和/或双歧杆菌的特异性刺激。
母乳似乎也具有促双歧杆菌生长(bifidogenic)作用,因为母乳喂养婴儿体内存在的主要的细菌为双歧杆菌。相反,婴儿配方食品喂养的婴儿的细菌群集中双歧杆菌是非主要的或较次要的,并且细菌种类也更多样(Harmesen等,2000,J Pediatr Gastroenterol Nutr 30,61-67)。据信人乳中存在的不可消化的糖是这种促双歧杆菌生长作用的原因。在母乳喂养婴儿的结肠和排泄物中发现的主要的SCFA为乙酸。此外,还发现了高浓度的乳酸。
已提出了多种组合物以尝试模拟母乳喂养婴儿的SCFA的生成状况。已经提出了如WO 0008948中所述的小的不可消化寡糖的结合物(combination)或小的不可消化寡糖与不可消化多糖的结合物。然而,使用小的益生元(prebiotic)寡糖的主要缺点在于其显著提高了肠内的渗透压负载,这可能导致有害的轻泻作用或者甚至更严重的情况——腹泻。
使用高分子量或高聚合度(DP)的不可消化多糖具有使产物粘度提高的缺点。此外,DP高于300的大的多糖更难由乳酸细菌和双歧杆菌发酵。
因此,需要一种包含益生元的营养配方食品,所述益生元包括相对大的不可消化多糖,所述配方食品对肠内短链脂肪酸的生成具有期望的效果,并且不过度地提高肠的渗透压负载和/或产物粘度。
发明内容
本发明人惊奇地发现,将部分水解的瓜耳胶(PHGG)与菊粉或不可消化的聚糊精结合给予,可以达到许多协同有益的效果。这些效果类似于小的不可消化寡糖的结合物的效果,然而并没有不良地提高肠的渗透压负载和/或产物粘度。
菊粉和部分水解的瓜耳胶的结合物为本领域已知,例如可从WO2004026294得知。此外,癌症病人的营养流体产品Resource supportTM也含菊粉和Benefiber。然而,至今尚未认识到这种不可消化多糖的结合物提供了有益的短链脂肪酸生成状况,使得它们特别适于在婴儿营养物中使用。
已发现的有益效果在给予多糖与PHGG的结合时比单独组分时或例如菊粉和不可消化多糖的结合时更显著。这表明部分水解的聚半乳甘露聚糖与果聚糖或者部分水解的聚半乳甘露聚糖与不可消化的聚糊精具有协同作用。此外,据信这些结果表明含部分水解的树胶和另一种不同于水解的树胶并且DP在10和300之间的可发酵、不可消化多糖的婴儿营养物具有协同作用。
特别地,出人意料地发现,本发明混合物的发酵产生以下效果:a)SCFA生成总量的协同增长;b)乳酸生成总量的协同增长;c)乙酸和乳酸相对量的增长;d)丁酸、戊酸和带支链的短链脂肪酸的相对量的降低;和/或e)每mmol SCFA气体生成量的降低。
因此,将本发明的不可消化多糖的结合物包含于婴儿营养物中,可以得到一种与母乳功能高度类似的组合物。因此,在一个实施方案中,本发明提供了部分水解的半乳甘露聚糖与选自果聚糖或不可消化聚糊精的多糖的结合物用于制备可产生与母乳喂养婴儿的结肠环境基本类似的组合物的用途。
因此,可以通过给予本发明组合物达到以下一种或多种生理效果:双歧杆菌和/或乳酸细菌的显著增长;乳酸的显著增长和/或总的SCFA的显著增长;乙酸相对量的显著提高;丁酸相对量的显著降低;异丁酸、戊酸和异戊酸总量的显著降低;气体生成的减少;包括结肠最远端部分的发酵在内的更长且更均匀的发酵,以及结肠最近端部分的高度发酵。
通过这些乳酸细菌、双歧杆菌、乳酸水平、SCFA水平和生成状况的变化,本发明组合物提供了以下一种或多种效果:
-SCFA生成位点处肠渗透性的降低。这对于预防疾病及保持健康,尤其是预防产生过敏非常重要。
-自发收缩和结肠肌肉紧张的发生率的降低,从而导致更少的痉挛、更少的急腹痛和更少的腹部疼痛。
-钙离子吸收的提高,这对于骨的矿化作用和骨的发育而言很重要。
-肠黏膜的黏液生成的增长,提供了针对病原体附着和群集的保护。
-降低的pH,产生对病原菌的抑制。
这种部分水解的半乳甘露聚糖和其它不可消化多糖对于SCFA和乳酸形成的新的协同相互作用,导致了在腹泻、急腹痛和/或腹部痉挛和过敏的治疗或者预防方面的新用途。
包含这些益生元混合物的本发明营养组合物也可用于患有肠问题的成年人,例如患有炎性肠病(IBD)或者应激性肠综合征(IBS)的成年人。
具体实施方式
本发明提供了一种向婴儿提供营养的方法,所述方法包括将营养组合物给予婴儿,其特征在于该组合物包括:
每100克干重所述营养组合物0.1至15克聚合度(DP)在10和300之间的不可消化、可发酵的部分水解树胶;和
每100克干重所述营养组合物0.1至15克不同于部分水解树胶的聚合度(DP)在10和300之间的不可消化、可发酵的可溶性多糖。
本发明还提供了一种包含5至16en%的蛋白质、35至60en%的脂肪和25至75en%的碳水化合物的组合物,其包括:
每100克干重组合物0.1至15克聚合度(DP)在10和300之间的不可消化、可发酵的部分水解树胶;和
每100克干重组合物0.1至15克不同于部分水解树胶的DP在10和300之间的不可消化、可发酵的可溶性多糖。
本说明书中所用的聚合度(DP)的含义为在多聚物或低聚物中连接在一起的单体单元的数目。
本说明书中所用的术语“可溶性”,当与多糖、纤维或寡糖有关时,其含义为该物质根据L.Prosky等,J.Assoc.Off.Anal.Chem.71,1017-1023(1988)所述方法为至少50%可溶。
本说明书中所用的术语“可发酵”指的是能够在结肠中被微生物(厌氧)分解为较小分子的能力,所述较小分子特别为短链脂肪酸和乳酸。可发酵性可由例如Am.J.Clin.Nutr.53,1418-1424(1991)中所述方法测定。
树胶
本发明组合物每100克干重包含0.1至15克聚合度(DP)在10和300之间的不可消化、可发酵的部分水解树胶。水解的树胶优选为水溶性的。本说明书中所用的术语“部分水解”指的是已经过水解(例如热、机械、酸或酶促的)的并且尚未水解为其单糖单元的组合物。
本说明书中所用的术语“树胶”指的是通常可获得的天然树胶,并且更特别地为魔芋胶、黄原胶、瓜耳胶(瓜尔豆胶)、槐(角豆)豆胶、他拉豆胶(tara bean gum)、黄蓍树胶、阿拉伯树胶或金合欢胶、刺梧桐树胶、印度树胶、藻胶、talha胶、吉兰糖胶和其它树胶。
在本发明的一个实施方案中,优选使用不可消化、可发酵的部分水解的半乳甘露聚糖。半乳甘露聚糖由线形主链上的β-(1,4)-D-吡喃甘露糖基(mannopyrasyl)单元和通过α-(1,4)-D键连接在其上的半乳糖支链组成。根据一个特别优选的实施方案,使用瓜耳胶、槐豆胶和/或他拉豆胶。
部分水解的半乳甘露聚糖可通过部分水解或有限水解获得。通过酶如β-甘露聚糖酶和/或由化学/物理处理减小半乳甘露聚糖树胶的分子大小。通过这种处理将25℃下10%溶液的粘度减低至20cps以下,此值由布鲁克菲尔德粘度计测定。
根据特别优选的实施方案,使用部分水解的瓜耳胶(PHGG)。瓜耳胶为一种可由瓜尔豆(cyamopsis tetragonolobus)的胚乳获得的多糖,其主要包含高分子量的水胶体的多糖,该多糖由通过糖苷键结合的半乳糖和甘露糖单元组成。具体地说,瓜耳胶优选由α-D-吡喃半乳糖基单元和(1→4)β-D-吡喃甘露糖基单元的直链组成,所述单元通过(1→6)键连接。PHGG可由Novartis Nutrition公司的商标名为Benefiber或日本Taiyo Kagaku的商标名为“Sunfiber AG”商购获得。水解的树胶优选为具有较好溶解度的聚集态形式。
本发明组合物每100克干重优选包括0.5至8克、更优选1至5克聚合度(DP)在10和300之间的不可消化、可发酵的部分水解树胶,所述树胶特别为PHGG。优选地,这些用量的不可消化、可发酵的部分水解树胶以聚合度(DP)在20和150之间、更优选25和100之间的不可消化、可发酵的部分水解树胶形式提供。
多糖
本发明组合物每100克干重包括0.1至15克不同于部分水解树胶的DP在10和300之间的不可消化、可发酵的可溶性多糖。所述不可消化、可发酵的可溶性多糖优选选自果聚糖和不可消化的聚糊精。
本发明组合物优选包括0.5至8克、更优选1至5克不可消化、可发酵的多糖。
术语“果聚糖”指的是DP在10至300之间的、优选在20至300之间的包含一个含至少10个β-连接果糖单元的链的多糖碳水化合物。优选使用菊粉。菊粉可由商标名为“Raftilin HP”(Orafti)获得。本说明书中所用的术语“菊粉”是指DP在10至300之间的具有至少90%果糖单元的葡萄糖封端的果糖链。菊粉可表示为GFn,其中G代表葡糖基单元,F代表果糖基单元,n为相互连接的果糖基单元的数目,n为9或者更大。然而,由于处理过程中的水解,小部分的菊粉分子可能不具有末端葡萄糖单元。果聚糖的平均DP优选为至少15,更优选为至少20或更高,最高达300。在菊粉中果糖单元通过β(2→1)键连接。
本发明组合物优选包括0.5至8克、更优选1至5克果聚糖。
不可消化的聚糊精指DP为10至50、优选为10至20的耐消化的(麦芽糖)糊精或耐消化的聚葡萄糖。不可消化的聚糊精为至少75%不可消化,优选至少90%不可消化。所述不可消化的聚糊精优选由水解反应和转葡糖苷作用反应相结合制得。在一个优选实施方案中,所述不可消化的聚糊精包括α(1→4)、α(1→6)糖苷键和1→2、1→3键。不可消化的聚糊精可由例如Matsutami Inductries的商标名为”Fibersol 2”或Danisco的Litesse获得。
本发明组合物优选包括0.5至8克、更优选1至5克不可消化聚糊精。
比例
优选地,本发明组合物中不可消化、可发酵的多糖:不可消化、可发酵的部分水解树胶的重量比为1∶19至19∶1,优选为1∶4至4∶1,更优选为0.5∶1至2∶1。当两种不可消化的多糖的比例接近1∶1时,两种不可消化的多糖的协同效应将越来越明显。
液体组合物
本发明组合物优选以液体形式给予。为了满足热量需要,本发明组合物优选含有50至200千卡/100ml,更优选含有60至90千卡/100ml。本发明组合物的摩尔渗透压浓度通常为150至420mOsmol/l,优选260至320mOsmol/l。低的摩尔渗透压浓度的目的是为了降低胃肠压力,例如降低腹泻的发生率,特别是对于婴儿。
该组合物优选为液体形式,粘度在35cps以下。如果合适,该组合物也可为粉末形式,该粉末形式可用水复原形成液体。
日剂量
当组合物为液体形式时,优选每日的给予体积为每天约80至2500ml,更优选为约450至1000ml,此用量为适合于婴儿的量。婴儿为年龄为0至36个月的人类。
本发明组合物的日有效剂量优选包括1至40g可发酵、不可消化的多糖/天,优选为2至10g/天,其中所述多糖包括水解的树胶和可溶性、可发酵、不可消化的多糖。a)部分水解树胶(优选PHGG)和b)优选选自果聚糖或不可消化聚糊精的可溶性不可消化的多糖的浓度之和优选为0.2至5g/100ml,更优选为0.2至3.5g/100ml,再更优选为每100ml 0.3至2.4克,最优选为每100ml 0.35至1.0克。
治疗
本发明组合物可有利地在治疗和/或预防腹泻、(胃肠)感染、急腹痛、腹部痉挛、腹部疼痛、应激性肠综合征(IBS)、炎性肠病(IBD)、过敏、湿疹、气喘和/或特应性疾病的方法中使用。在一个优选的实施方案中,本发明在治疗或预防过敏或变态反应的方法中使用。
本发明组合物优选口服给予。该组合物可特别地在向婴儿提供营养物和/或刺激婴儿成长的方法中使用。由于该组合物对刺激肠内微生物区系的成熟特别有用,因此该组合物有利地给予0-6岁的婴儿,优选0-48个月的婴儿,更优选给予0-18个月的婴儿,再更优选给予0-12个月的婴儿。婴儿年龄越小,乳酸杆菌占优势的肠内微生物区系越重要。
常量营养物
本发明组合物含有5至16en%蛋白质、35至60en%脂肪以及25至75en%碳水化合物,优选含有5至12.0en%蛋白质、39至50en%脂肪以及40至55en%碳水化合物。(en%是能量百分比的缩写,代表各成分对制剂总热值的相对贡献量)。
本发明组合物优选每100ml含1.4至6g蛋白质源(proteinsource)。本发明组合物相应地每100g干重含8.5至19g。蛋白质源可包括较大的完整蛋白质、水解蛋白质、肽或游离氨基酸或者其混合物。合适的蛋白质源为牛乳蛋白、酪蛋白、乳清和豆蛋白。蛋白质含量基于凯氏百分比,N*6.38。本发明组合物优选每100ml还含有2.1至6.5g脂肪,每100ml含有0.3至1.5g亚油酸(LA),每100ml含有至少50mgα-亚油酸(ALA),其中LA/ALA之比为5至15。以干重计,本发明组合物优选每100g含有12.5至30g脂肪、1.8至12.0g LA和至少0.30g ALA,其中LA/ALA之比为5至15。饱和脂肪酸的量优选为总脂肪酸的10至58重量%,以总脂肪酸的重量计,单不饱和脂肪酸的浓度为17至60%,以总脂肪酸的重量计,多不饱和脂肪酸的浓度为11至36%。上述ALA和LA的量和比值的优点在于,可获得n-3和n-6多不饱和脂肪酸的平衡的生物合成。优选本发明组合物含长链多不饱和脂肪酸(LC PUFA),例如二十碳五烯酸(EPA)、二十二碳六烯酸(DHA)和花生四烯酸(AA)。合适的脂类来源为乳脂、低芥酸菜子油、红花油、向日葵油、橄榄油、椰子油、鱼油等,或者上述物质的包含合适脂肪酸的成分或混合物。
本发明组合物优选每100ml含6至19g可消化的碳水化合物,优选6-19克乳糖。其它合适的可消化的碳水化合物来源为麦芽糖糊精、淀粉、蔗糖、葡萄糖和麦芽糖。
益生元
根据在一个优选的实施方案,本发明组合物含有益生菌。益生菌为对人类健康具有有益效果的活的微生物食物成分。益生菌通常称为“乳酸细菌”,如此称之是因为乳酸为碳水化合物发酵所生成的主要产物。本发明组合物优选含乳酸杆菌属和/或双歧杆菌属中的种类。双歧杆菌和乳酸杆菌为特别是在母乳喂养婴儿的结肠内存在的细菌。益生元的存在还能够促进多糖混合物在结肠中发酵成SCFA(尤其为乙酸)和乳酸,从而进一步促进健康的结肠环境的形成,尤其是对于婴儿而言。益生元的浓度优选为每100ml 1*107菌落生成单位(cfu)至2*1010cfu,优选每100ml 1*108cfu至2*109cfu。以干重计,所述浓度优选为6*107至1*1011cfu/100g,优选6*108至3*1010cfu/100g。
附图说明
附图:婴孩新鲜排泄物对以下物质体外发酵48h后生成的短链脂肪酸,以mmol/g不可消化的多糖(IP)计:部分水解的瓜耳胶(PHGG)、菊粉、不可消化的聚糊精(ID)、部分水解的瓜耳胶和菊粉的混合物(重量比1∶1)、部分水解的瓜耳胶和不可消化的聚糊精的混合物(重量比1/1)以及菊粉和不可消化的聚糊精的混合物。iC4,5总和为戊酸、异丁酸和异戊酸的总和。用空白发酵校正数据。该附图表明PHGG与菊粉或不可消化聚糊精的结合物协同改进了SCFA的生成。此结果表明这些结合物在婴儿食物中的有利应用。
实施例
实施例1:对发酵模式的协同效应
材料:
从婴儿配方食品喂养的婴孩的新鲜排泄物中获得微生物区系。将从三个年龄为6至12个月的瓶哺婴孩获得的新鲜排泄物集中起来,并在2h内放入防腐介质(preservative medium)中。
防腐介质:经缓冲(buffered)的蛋白胨20.0g/l、L-半胱氨酸-HCl0.5g/l、巯基乙酸钠0.5g/l、刃天青片剂每升1片,用1M NaOH或HCl调节至pH 6.7±0.1。微波煮沸。将25ml介质装入30ml血清瓶。121℃下灭菌15分钟。
McBain & MacFarlane培养基:经缓冲的蛋白胨水3.0g/l、酵母提取物2.5g/l、黏蛋白(刷状缘)0.8g/l、胰蛋白胨3.0g/l、L-半胱氨酸-HCl 0.4g/l、胆汁盐0.05g/l、K2HPO4·3H2O 2.6g/l、NaHCO3 0.2g/l、NaCl 4.5g/l、MgSO4·7H2O 0.5g/l、CaCl2 0.228g/l、FeSO4·7H2O 0.005g/l。将该培养基装入500ml Scott瓶中并在121℃下灭菌15分钟。
缓冲介质:K2HPO4·3H2O 2.6g/l、NaHCO3 0.2g/l、NaCl 4.5g/l、MgSO4·7H2O 0.5g/l、CaCl2 0.228g/l、FeSO4·7H2O 0.005g/l。用K2HPO4或NaHCO3调节至pH 6.3±0.1。将该介质装入500ml Scott瓶中并在121℃下灭菌15分钟。
排泄物悬浮液:将经防腐处理的排泄物溶液以13,000rpm离心15分钟。除去上清液,将排泄物与McBain & MacFarlane培养基以1∶5的重量比混合。
所用的部分水解瓜耳胶为由Taiyo获得的SunFiber。所用的不可消化的聚糊精为由Matsutani获得的Fibersol-2。所用的果聚糖为由Orafti获得的RaftilineHP。
方法:
2h内将新鲜的婴孩排泄物与防腐介质混合并在4℃下贮存0-3h。在贮存的3h内开始进行发酵试验。
发酵:
将15.0ml的排泄物悬浮液分别与以下各物质在瓶中充分混合:a)500mg SunFiber、b)500mg Fibersol-2、c)500mg RaftlineHP、d)250mgSunFiber+250mg RaftlineHP、e)250mg SunFiber+250mg Fibersol-2、f)250mg RaftlineHP+250mg Fibersol-2或者g)没有任何添加(空白)。提取t=0时的试样(0.5ml)。将得到的14.5ml悬浮液倒入装有250ml缓冲介质的250ml瓶中的渗析管中。将瓶子密封好,在37℃下培养。在3、24和48小时后用皮下注射器从渗析管(0.5ml)或渗析缓冲液(1.0ml)中取样,并立即放置在冰上以停止发酵。随后在-20℃下保存试样。
SCFA分析:将试样在冰水中解冻,在MilliQ中稀释10倍。将350μl试样与200μl 5%(v/v)甲酸、100μl 1.25g/l 2-乙基丁酸(Sigma-Aldrich,Zwijndrecht,荷兰)和350μl MilliQ混合。通过装有火焰离子化检测器的Varian 3800气相色谱(GC)(Varian,Inc.,Walnut Creek,美国)定量测定乙酸、丙酸、正丁酸、异丁酸和正戊酸。在80℃下将0.5μl试样注入柱内(Stabilwax,15m×0.53mm,膜厚度1.00μm,Restek Co.,美国),使用氦作为载气(3.0psi)。新柱在200℃下老化过夜。在注入试样后,以16℃/分钟的速度将烘箱升温到160℃,然后以20℃/分钟的速度升温到220℃,最后在220℃下保温1.5分钟。注射器和检测器的温度为200℃。每十个试样后注射0.5μl的1%(v/v)甲酸清洗柱子以避免柱的记忆效应,然后注入0.5μl标准SCFA混合物(1.77mM乙酸、1.15mM丙酸、0.72mM正丁酸、0.72mM异丁酸、0.62mM正戊酸,由Sigma-Aldrich,Zwijndrecht,荷兰获得)以监测是否发生记忆效应。使用2-乙基丁酸作为内标测定SCFA的水平。
乳酸分析:将试样在冰上解冻,以14,000rpm离心5分钟。将100μl上清液在100℃下加热10分钟以使所有酶失活。使用L-乳酸检测试剂盒和D-乳酸-脱氢酶(Boehringer Mannheim,Mannheim,德国)以酶促的方式测定L-乳酸和D-乳酸的浓度。
结果:
结果如附图所示。附图表明,与单独组分或者考虑到单独组分的加和效应时的情况相比,PHGG和菊粉的混合物的使用令人惊奇地使每克不可消化的多糖生成更多的SCFA——特别是乙酸。加和效应为由仅RaftilinHP发酵和仅SunFiber发酵的结果计算得到的发酵结果的平均。这些结果显示了PHGG和菊粉的协同效应,且表明了(婴儿)营养物中本发明组合物的协同效应。
PHGG和菊粉混合物的发酵表明,与单独组分发酵时相比,异丁酸加上异戊酸加上戊酸的量和百分比显著更低(PHGG 0.029,菊粉0.021,PHGG+菊粉0.010,单位为mmol/g不可消化的多糖)。
PHGG和不可消化聚糊精的混合物的发酵令人惊奇地产生了更多的SCFA——尤其是乙酸,其超过了两种不可消化多糖的理论加和效应。PHGG和不可消化聚糊精的混合物的发酵导致了乙酸量的协同提高,而丁酸量降低,并且异丁酸加上异戊酸加上戊酸的(相对)量降低(PHGG 0.029、ID 0.028、PHGG+ID 0.017mmol/g不可消化的多糖)。
出乎意料地,不可消化聚糊精和菊粉的结合物的发酵并没有使SCFA的生成协同增加,而是使SCFA的生成降低。它还导致了异丁酸加上异戊酸加上戊酸的相对量的提高。
在婴孩排泄物体外发酵3h后测定乳酸的生成。表1显示出在该时间点上生成的代谢终产物。PHGG与菊粉或不可消化聚糊精的混合物中观察到乳酸生成的协同增加。菊粉和不可消化聚糊精的结合物并没有表现出这一效应。
表1
供试组分 | 乳酸(μmol/g不可消化的多糖) |
SunFiber | 5 |
RaftilinHP | 0 |
Fibersol-2 | 68 |
SunFiber+Fibersol-2 | 89 |
SunFiber+RaftilinHP | 24 |
Fibersol-2+RaftilinHP | 44 |
SCFA生成的动力学
表2显示了以mmol/g不可消化的多糖计的SCFA生成的动力学(空白校正)(48h内的生成的总SCFA的百分比)。PHGG与菊粉的结合物显示出在24和48h之间仍生成了大量的SCFA,表明在结肠的远端部分仍有SCFA生成。然而,在最初的3h内也生成了大量的SCFA。
PHGG+不可消化聚糊精的混合物也导致了在最后24h和最初3h期间SCFA生成的增长。这些效应具有协同作用;它们比单独组分的加和效应更大。
表2
时间间隔(小时) | |||
0-3小时 | 3-24小时 | 24-48小时 | |
SunFiber | 0.41(8%) | 3.92(78%) | 0.68(14%) |
RaftilinHP | 0.21(4%) | 4.04(82%) | 0.70(14%) |
Fibersol-2 | 0.42(18%) | 1.42(61%) | 0.50(21%) |
SunFiber+Fibersol-2 | 0.57(14%) | 2.67(67%) | 0.76(19%) |
SunFiber+RaftilinHP | 0.34(5%) | 4.15(66%) | 1.84(29%) |
以下实施例为含可发酵多糖的协同混合物的组合物的非限制性实施例。
实施例2:
液体组合物,将13.5g粉末用水复原至最终体积100ml后制得,每100ml最终体积包括:
能量: 67千卡
蛋白质: 8en%
1.4g
0.6g酪蛋白
0.8g乳清
可消化的碳水化合物: 45en%
7.5g
7.3g乳糖
0.2g其它碳水化合物
脂肪: 47en%
3.5g
1.5g饱和
1.5g单不饱和
0.5g多不饱和
0.4g亚油酸
0.07gα-亚油酸
不可消化的多糖 0.4g
0.1g果聚糖
0.3g部分水解的瓜耳胶
摩尔渗透压浓度: 300mOsmol/l
该组合物还含有含量依照婴儿奶粉配方国际准则的矿物质、微量元素、维生素和胆碱以及牛磺酸。
实施例3:
液体组合物,将15.8g粉末用水复原至最终体积100ml后制得,每100ml最终体积包括:
能量: 72千卡
蛋白质: 11en%
1.9g(部分水解的乳清蛋白)
可消化的碳水化合物: 40en%
8.7g
3.9g糖
3.0g乳糖
0.9g其它
4.8g多糖
2.0g淀粉
2.8g其它
脂肪: 40en%
3.3g
1.4g饱和(包括1.4gβ-棕榈酸酯)
1.4g单不饱和
0.5g多不饱和
0.43g亚油酸
0.08gα-亚油酸
不可消化的多糖: 0.8g
0.4g不可消化的聚糊精
0.4g部分水解的瓜耳胶
益生元: 1.5 108菌落生成单位的双歧杆菌
摩尔渗透压浓度: 270mOsmol/l
该组合物还含有含量依照婴儿改进配方食品(follow on formula)国际准则的矿物质、微量元素、维生素和胆碱以及牛磺酸。
实施例4:
液体组合物,包含:
每100ml:
能量: 150千卡
蛋白质: 9en%
3.4g(酪蛋白)
可消化的碳水化合物: 50en%
18.8g
3.0g蔗糖
0.9g麦芽糖
14.3g多糖
0.6g其它
脂肪: 41en%
6.8g 6.9g
0.7g饱和
4.1g单不饱和
2.0g多不饱和
1.62g亚油酸
0.34gα-亚油酸
不可消化的多糖: 1.5g
0.8g果聚糖
0.7g部分水解的瓜耳胶
摩尔渗透压浓度: 390mOsmol/l
该组合物还含有含量依照国际推荐的矿物质、微量元素、维生素、肉碱、牛磺酸和胆碱。
Claims (17)
1.一种不可消化的多糖的结合物用于制造在向婴儿提供营养的方法中使用的营养组合物的用途,所述方法包括将营养组合物给予婴儿,所述组合物包括:
a)每100克干重所述营养组合物0.1至15克聚合度(DP)在10和300之间的不可消化、可发酵的部分水解树胶;和
b)每100克干重所述营养组合物0.1至15克不同于部分水解树胶的聚合度(DP)在10和300之间的不可消化、可发酵的可溶性多糖。
2.权利要求1的营养组合物的用途,其中所述组合物还包含5至16en%的蛋白质、35至60en%的脂肪和25至75en%的碳水化合物。
3.权利要求1或2的营养组合物的用途,其中每100ml所述组合物还包含9至16g可消化的碳水化合物。
4.前述权利要求的任一项的营养组合物的用途,其中所述方法包括改善肠内微生物区系。
5.前述权利要求的任一项的营养组合物的用途,其中所述方法包括治疗和/或预防过敏、特应性疾病、湿疹或者肠痉挛或者急腹痛。
6.前述权利要求的任一项的组合物的用途,其中所述方法包括治疗和/或预防肠感染、腹泻或胃肠道的炎性病症。
7.前述权利要求的任一项的用途,其中所述营养组合物每日剂量提供1至40g不可消化、可发酵的多糖。
8.一种组合物,其包含5至16en%的蛋白质、35至60en%的脂肪和25至75en%的碳水化合物,所述组合物包括:
a)每100克干重所述组合物0.1至15克聚合度(DP)在10和300之间的不可消化、可发酵的部分水解树胶;和
b)每100克干重所述组合物0.1至15克不同于部分水解树胶的DP在10和300之间的不可消化、可发酵的可溶性多糖。
9.权利要求8的组合物,所述组合物包括:
a)0.1至15克聚合度(DP)在10和300之间的部分水解半乳甘露聚糖;和
b)0.1至15克DP在20和300之间的果聚糖;或0.1至15克DP在10和300之间的不可消化的聚糊精。
10.权利要求8或9的组合物,所述组合物包括0.1至15克聚合度(DP)在10和300之间的部分水解瓜耳胶。
11.权利要求8-10的组合物,其中DP在10和300之间的部分水解半乳甘露聚糖:DP在20和300之间的果聚糖或DP在10和300之间的不可消化聚糊精的重量比为19∶1至1∶19。
12.权利要求8-11的组合物,所述组合物的摩尔渗透压浓度为100至420m0smol/l且粘度为35cps以下。
13.权利要求8-12的组合物,所述组合物的热量密度为50至200千卡/100ml。
14.权利要求8-13的组合物,所述组合物每100g干重包含1.8至12.0g亚油酸(LA),每100g干重包含至少0.3gα-亚油酸(ALA),其中LA/ALA之比为5至15,其特征在于饱和脂肪酸的浓度为10%至58%(以总的脂肪酸计),以总的脂肪酸计单不饱和脂肪酸的浓度为17至60%,并且,以总的脂肪酸计多不饱和脂肪酸的浓度为11至36%。
15.前述权利要求的任一项的组合物,所述组合物包括5至12.0en%的蛋白质、39至50en%的脂肪和40至55en%的碳水化合物,
16.权利要求8-15的组合物用于制造在治疗和/或预防炎性肠病和/或应激性肠综合征的方法中使用的营养组合物的用途。
17.权利要求8-15的组合物用于制造在向婴儿提供营养的方法中使用的营养组合物的用途。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04077393A EP1629727A1 (en) | 2004-08-24 | 2004-08-24 | Composition containing fermentable polysaccharides |
EP04077393.9 | 2004-08-24 | ||
PCT/NL2005/000613 WO2006022544A1 (en) | 2004-08-24 | 2005-08-24 | Composition containing fermentable polysaccharides |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101043822A true CN101043822A (zh) | 2007-09-26 |
CN101043822B CN101043822B (zh) | 2011-01-12 |
Family
ID=34928472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800355224A Expired - Fee Related CN101043822B (zh) | 2004-08-24 | 2005-08-24 | 含有可发酵多糖的组合物 |
Country Status (9)
Country | Link |
---|---|
US (2) | US8076313B2 (zh) |
EP (2) | EP1629727A1 (zh) |
CN (1) | CN101043822B (zh) |
AU (1) | AU2005275578B2 (zh) |
CA (1) | CA2578093C (zh) |
ES (1) | ES2470390T3 (zh) |
PL (1) | PL1781117T3 (zh) |
RU (1) | RU2385646C2 (zh) |
WO (1) | WO2006022544A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104987432A (zh) * | 2008-08-20 | 2015-10-21 | 卡吉尔公司 | 新型聚葡萄糖材料 |
CN114641208A (zh) * | 2019-11-27 | 2022-06-17 | 雀巢产品有限公司 | 用于降低应激障碍的新型组合物 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080126195A1 (en) | 2004-07-22 | 2008-05-29 | Ritter Andrew J | Methods and Compositions for Treating Lactose Intolerance |
EP2341785A1 (de) * | 2008-10-29 | 2011-07-13 | Preox-Rs GmbH | Ernährungszusammensetzung enthaltend omega- 3 -fettsäuren und mct |
WO2010098822A1 (en) | 2009-02-24 | 2010-09-02 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
EP3202406A1 (en) | 2010-04-28 | 2017-08-09 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
EP2910132A1 (en) * | 2010-12-06 | 2015-08-26 | N.V. Nutricia | Fermented infant formula |
JP6160011B2 (ja) * | 2013-02-06 | 2017-07-12 | 松谷化学工業株式会社 | IgA分泌促進剤 |
EP3232820B1 (en) | 2014-12-19 | 2020-01-29 | Société des Produits Nestlé S.A. | Infant nutrition with hydrolysed protein, ionic calcium and palmitic acid |
MX2018007398A (es) * | 2015-12-31 | 2018-08-15 | Nestec Sa | Composicion para mejorar la sensacion bucal. |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5827526A (en) * | 1995-07-11 | 1998-10-27 | Abbott Laboratories | Use of indigestible oligosaccharides to prevent gastrointestinal infections and reduce duration of diarrhea in humans |
TW408153B (en) * | 1998-01-09 | 2000-10-11 | Asahi Chemical Ind | Cellulose-containing composite, process for its preparation and use thereof |
DE19836339B4 (de) | 1998-08-11 | 2011-12-22 | N.V. Nutricia | Kohlenhydratmischung |
US6248390B1 (en) * | 2000-02-22 | 2001-06-19 | Suzanne Jaffe Stillman | Fiber-water—water containing soluble fiber |
US20040087490A1 (en) * | 2002-09-20 | 2004-05-06 | Troup John P. | Nutritional compositions |
GB0229015D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Nutrition Ag | New Compound |
-
2004
- 2004-08-24 EP EP04077393A patent/EP1629727A1/en not_active Withdrawn
-
2005
- 2005-08-24 WO PCT/NL2005/000613 patent/WO2006022544A1/en active Application Filing
- 2005-08-24 CN CN2005800355224A patent/CN101043822B/zh not_active Expired - Fee Related
- 2005-08-24 AU AU2005275578A patent/AU2005275578B2/en not_active Ceased
- 2005-08-24 US US11/574,120 patent/US8076313B2/en not_active Expired - Fee Related
- 2005-08-24 PL PL05775174T patent/PL1781117T3/pl unknown
- 2005-08-24 ES ES05775174.5T patent/ES2470390T3/es active Active
- 2005-08-24 CA CA2578093A patent/CA2578093C/en not_active Expired - Fee Related
- 2005-08-24 EP EP05775174.5A patent/EP1781117B1/en not_active Not-in-force
- 2005-08-24 RU RU2007110843/13A patent/RU2385646C2/ru not_active IP Right Cessation
-
2011
- 2011-11-10 US US13/294,002 patent/US8461131B2/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104987432A (zh) * | 2008-08-20 | 2015-10-21 | 卡吉尔公司 | 新型聚葡萄糖材料 |
CN114641208A (zh) * | 2019-11-27 | 2022-06-17 | 雀巢产品有限公司 | 用于降低应激障碍的新型组合物 |
Also Published As
Publication number | Publication date |
---|---|
RU2385646C2 (ru) | 2010-04-10 |
EP1629727A1 (en) | 2006-03-01 |
AU2005275578A1 (en) | 2006-03-02 |
CA2578093A1 (en) | 2006-03-02 |
EP1781117B1 (en) | 2014-03-12 |
US8076313B2 (en) | 2011-12-13 |
AU2005275578B2 (en) | 2011-12-15 |
US8461131B2 (en) | 2013-06-11 |
US20120058968A1 (en) | 2012-03-08 |
CA2578093C (en) | 2013-10-15 |
PL1781117T3 (pl) | 2014-08-29 |
WO2006022544A1 (en) | 2006-03-02 |
ES2470390T3 (es) | 2014-06-23 |
US20080280852A1 (en) | 2008-11-13 |
CN101043822B (zh) | 2011-01-12 |
RU2007110843A (ru) | 2008-10-10 |
EP1781117A1 (en) | 2007-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101043822A (zh) | 含有可发酵多糖的组合物 | |
CN1620257A (zh) | 包含果胶的基质形成组合物 | |
US8691213B2 (en) | Protein free formula | |
CN1731938A (zh) | 益生元组合物 | |
RU2469558C2 (ru) | Применение пробиотиков и волокон при диарее | |
CN1784151A (zh) | 合生素组合物 | |
CN101048167A (zh) | 刺激免疫的婴儿营养品 | |
CN101945589A (zh) | 用于改善肠道微生物群的非消化性碳水化合物的用途 | |
BRPI0611020A2 (pt) | uso de polidextrose para estimular os atributos funcionais de oligossacarìdeos do leite humano em crianças pequenas alimentadas com fórmula | |
CN101043904A (zh) | 含有不可消化寡糖的营养组合物 | |
BR112015000136B1 (pt) | fibra alimentar para uso no tratamento de um efeito colateral gastrintestinal de uma nutrição ou medicamento | |
US20200315235A1 (en) | Normalization of the Intestinal Microbiota Composition in Infants or Toddlers Fed with an Amino Acid-Based Nutritional Composition | |
CN104585749B (zh) | 具有高能含量的营养配方 | |
US20220248739A1 (en) | Non-digestible oligosaccharides for decreased colonic protein fermentation | |
KR20160113867A (ko) | 변비 개선용 조성물 및 이로 제조된 건강식품 | |
EP3860614B1 (en) | Dietary fiber for treating patients suffering from methylmalonic acidemia and propionic acidemia | |
WO2024089060A1 (en) | Antiregurgitation formula | |
CN113015440B (zh) | 包含尿素和不可消化寡糖的营养组合物 | |
WO2024089061A1 (en) | Thickened formula for allergic infants | |
Stewart et al. | Molecular weight of guar gum affects short-chain fatty acid profile in vitro | |
Kuntz et al. | INULIN: MODULATION OF INTESTINAL MICROBIOTA AND PROPECTS IN NEW PRODUCTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110112 Termination date: 20180824 |